Disinfectors Market Size, Share, Development and Demand Forecast to 2023

Disinfectors Market

Owing to the fact that cleaning and sanitation are vital for safety in the healthcare industries, the global market for disinfectants is driven by increased focus on hygiene and growing concerns over the spread of infectious diseases both at home and in public places. Rising demands in the food, beverage and healthcare industries is driving the global disinfectors market. Disinfectant chemicals are also becoming more common as an ingredient in various conventional and industrial cleaning products.

Explore Report at: https://www.psmarketresearch.com/market-analysis/disinfectors-market

Disinfectors are used for destroying pathogens for controlling infection.
Disinfection is an essential procedure that is performed for infection control in households and in healthcare facilities such as clinics, hospitals, elder care institutes and laboratories, using disinfectors and other infection control equipment such as sterilizers. Disinfectors are used to disinfect various medical instruments such as bedpans, surgical instruments, urine bottles and endoscopes. Disinfection is the process of destroying pathogenic organisms or rendering them inert. Hence, it ensures the hygiene condition of medical appliances that are used while providing medical services to people by healthcare workers.

The global disinfectant market can be categorized on the basis of disinfectors by product type, and disinfectors by applications. Based on disinfectors by product type, the global market for disinfectors is divided into washer, flusher and endoscope reprocessor. The washer is further divided into a single chamber (single door and double door) and multi chamber. On the basis of application, the global disinfectors market is classified into elder care, hospitals and clinics, and pharmaceuticals and life sciences.

Request for table of Content at: https://www.psmarketresearch.com/market-analysis/disinfectors-market/toc-sample

The rise in number of healthcare infrastructure in developing countries is one of the major trends in the disinfectors market. The large population in developing countries has opened up a large patient pool which eventually gives a rise in disposable income. The favorable economic conditions in most of the developing countries are propelling the infrastructural growth by establishing more medical care facilities and hospitals. Liquid products and aerosol are the most commonly used surface decontaminators, though a significant number of hospitals are employing UV disinfection systems as an surplus measure. Hence, another trend in the disinfectors market is the use of ultraviolet (UV) disinfectors as UV radiation inactivates micro-organisms by destroying the nucleic acids in viruses and bacteria.

Owing to the rise in number of chronic diseases, epidemic diseases such as H1N1 and aging population, North America dominates the disinfectors market followed by Europe.. Some of the major competitors in the global disinfectors market are Advanced Sterilization Products Division Ethicon US, LLC, Getinge AB, OLYMPUS CORPORATION and STERIS Corporation. Other prominent competitors in the market include ACTAVIS, American Biotech Labs, LLC, Amrep Inc, CareFusion Corporation, CCP Industries , Bio-Cide International, Inc., BIOTECHMEDICS US., Cantel Medical, Colgate-Palmolive Company., Swisher International, Inc., Diversey Inc.and many more.

 

Hypodermic Needle Market Analysis, Size, Development and Forecast to 2022

Hypodermic Needle Market

The global hypodermic needles market is expected to grow at a CAGR of 7.4% during 2016 – 2022. The growth of the global market is largely driven by the high demand for vaccines and increasing compliance of safety needles. High prevalence of needle stick injuries during drug administration is a key concern for healthcare providers across the globe. Improper disposal of syringe and needles is creating the demand for advanced safety mechanisms in hypodermic needles. Globally, approximately 16 billion injections are administered every year as per the World Health Organization (WHO); however, all the syringes and needles are not properly disposed of. Therefore, several benefits of safety needles such as ease of use during injection and safe delivery of drug or medication are increasing their popularity among healthcare providers.

Explore Report with Detailed TOC on “Global Hypodermic Needle Market” at: https://www.psmarketresearch.com/market-analysis/hypodermic-needles-market

Healthcare providers along with patients are getting aware about safety in drug delivery through syringes. This has created huge traction in the global market for developing advanced safety hypodermic needles with automatic features. Some of the other factors driving the growth of the global market include increasing prevalence of chronic and lifestyle associated diseases, and geriatric population. Increasing adoption of hypodermic needles in emerging economies is expected to create ample growth opportunities for the global market. However, alternative drug delivery method and high cost of hypodermic needles are the key barriers for the growth of the global market.

North America led the global hypodermic needle market in terms of size in 2015, owing to the increasing awareness of safe injectable technology, and increasing prevalence of chronic and lifestyle associated diseases. The U.S. contributed largest revenue to the North American as well as the global hypodermic needle market. The country is expected to remain the largest market for hypodermic needle globally during the forecast period.

Request For Sample Pages: https://www.psmarketresearch.com/market-analysis/hypodermic-needles-market/report-sample

Some of the players operating in the global market include Vygon S.A., Catalent, Inc., Terumo Corporation, Retractable Technologies, Inc., Connecticut Hypodermics, Inc., MedPro Safety Products Inc., B. Braun Melsungen AG, Albert David Ltd., Becton, Dickinson and Company, and Medtronic plc.

Ocular Pain Treatment Market Share, Development, Growth and Demand Forecast to 2023

The global ocular pain treatment market is expected to witness considerable growth due to increasing awareness about the eye disorders, technological advancement in ocular therapeutic and diagnostic test, and increasing number of lifestyle related ocular diseases. In addition, increasing geriatric population and increasing disposable income are further supporting the growth of the global ocular pain market.

The pharmaceutical companies are actively involved in the research and development of drugs for ocular pain. Loteprednol etabonate, a Mucus-Penetrating Particle platform technology based Phase III clinical trial drug of Kala Pharmaceuticals, Inc., is nanotechnology based products for the treatment of ocular pain.

Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market

Ocular pain is defined as the inflammation of middle layer of eye known as uvea. It can develop in optic nerve, blood vessels, muscles or other tissues that surround the eye.  Many factors such as infection, allergy, surgery or trauma including blow to the eye, foreign body and chemical injury can lead to ocular inflammation. It is important to manage ocular pain, else it can affect other parts of eyes such as cornea, retina, sclera, conjunctiva and the vasculature. Ocular pain is caused by several conditions such as glaucoma, ocular herpes, shingles, optic neuritis, dry eye and refractive error.

A large number of pharmaceutical companies are constantly working for the research and development of ocular pain treatment. However, certain factors such as high treatment cost, less awareness about the eye disease among population and lack of favorable government policy are the key factors hindering the growth of the global market during the forecast period.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market/toc-sample

Some of the key players operating in the global ocular pain market are ICON Bioscience Inc., Xigen S.A., Sylentis S.A., Bayer AG, Bristol Meyer Squibb Company, Merck and Co., Inc.,  Sun Pharmaceutical Industries Ltd., Reata Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc. and Ocular Therapeutix, Inc.

Personalized Medicine Market – Pipeline Analysis, Growth and Demand Forecast to 2023

Personalized Medicine Market

The global personalized medicine market is expected to witness significant growth due rapid advancement in diagnostic techniques, population heterogeneity across the globe, increasing awareness about the benefits of genetic makeup based drugs, and improving quality of disease diagnosis. The key vendors in the global personalized medicine market are focusing on oncology, infectious disease and cardiovascular targeted treatment and diagnostics.

Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/personalized-medicine-market

The pharmaceutical companies and biotechnology companies are actively involved in the research and development of personalized medicine. Different companies are developing and manufacturing biologics, such as blood products, vaccines, nutritional products, and gene therapies, to improve the quality of patient life. In December 2014, U.S. Food and Drug Administration (FDA) approved Lynparza, a poly (ADP-ribose) polymerase inhibitor as monotherapy in patients with deleterious or suspected deleterious germline breast cancer mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. Also in the same year, the organization approved the VIMIZIM, an enzyme replacement therapy for the treatment of patients with Morquio A syndrome.

National Cancer Institute, a part of the U.S. National Institutes of Health (NIH) defined personalized medicine as a form of medicine that uses information about a person’s genes, proteins and environment to prevent, diagnose and treat disease. In cancer, personalized medicine uses specific information about a person’s tumor to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis. Personalized medicine uses targeted therapies to treat specific types of cancer cells, such as HER2-positive breast cancer cells, and to develop tumor marker for the diagnosis of cancer.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/personalized-medicine-market/toc-sample

Some of the key players operating in the global personalized medicine market are GE Healthcare, Illumina Inc., Quest Diagnostics Incorporated, Abbott, Affymetrix, Inc., Bayer AG, F. Hoffmann-La Roche AG, AstraZeneca PLC, Pfizer Inc., Valeant Pharmaceuticals International, Inc., and Vertex Pharmaceuticals Incorporated.

Uterine Fibroid Treatment Market Size, Share, Growth and Forecast to 2023

The global uterine fibroid treatment market is witnessing considerable growth due to increasing female geriatric population, increasing healthcare expenditure, increasing prevalence of obesity, launch of technologically advanced fibroid treatment products and growing popularity of minimally invasive treatments   minimally invasive treatments. Moreover, growing prevalence of hormonal disorders or hormonal imbalance leading to fibroid formation is supporting the growth of the market. The increasing adoption of uterine fibroid treatment across the globe, owing to increasing incidence of cancer is also driving the growth of the market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/uterine-fibroid-treatment-market

The rapid growth in emerging economies and technological advancement in fibroid treatment with presence of minimally invasive treatment options is expected to create opportunities for the manufacturers of uterine fibroid treatment products. However, high cost of uterine fibroid treatment and presence of alternative treatment options are the key factors hampering the growth of the global market.

The increasing female aging population is propelling the growth of the global uterine fibroid treatment market. As reported by UN DESA (United Nation Department of Economic and Social Affairs) in the year 2013, the elder population is predominantly female. As women tend to live longer than men, while older women have outnumbered older men almost everywhere in the world. It further reported that in the year 2013, globally there were 85 men per 100 women in the age group 60 years or plus; and 61 men per 100 women in the age group 80 years or plus. The elderly population is more susceptible to gynecological problems, such as abnormal uterine bleeding, hormonal imbalance, and irregular menstrual cycle as compared to adults, which is fueling the demand of the global fibroid treatment market.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/uterine-fibroid-treatment-market/toc-sample

The key players operating in the global market are Boston Scientific Corporation, CooperSurgical, Inc., Karl Storz, Halt Medical, Inc., Merit Medical Systems, LiNA Medical USA, Olympus Corporation, and Richard Wolf GmbH.

Congestive Heart Failure Therapeutics Pipeline Analysis, 2017 – Clinical Trials and Results, Collaboration and Other Developments

Prevalence of congestive heart failure is witnessed to have increased, especially in Asia-Pacific and American region, due to rapid change in lifestyle of people, which in turn is results in various lifestyle diseases such as diabetes and high blood pressure. Additionally, other factors such as, sedentary nature of job, high cholesterol diet intake, lack of exercise, pollution, are also contributing to the increasing incidence of congestive heart failure, across the globe. The therapeutic pipeline for congestive heart failure is expected to grow in the next few years on account of increasing participation of various multinational pharmaceutical companies for the development of novel drugs, to be used in the treatment of congestive heart failure. According to the latest WHO report, it is estimated that there are around 26 million people suffering from problem of congestive heart failure, worldwide, with nearly 5.8 million cases having been registered in the U.S. only.

Explore Report at: https://www.psmarketresearch.com/market-analysis/congestive-heart-failure-therapeutics-pipeline-analysis

Congestive heart failure is a chronic progressive condition which affects the pumping power of the heart muscle. It is the stage where fluids build up around the heart and leads to inefficient pumping of blood to various organs of the body. Heart has four chambers; the upper half of the heart has two atria and the lower half of the heart has two ventricles. The ventricles pump blood to our body organs and tissues and the atria receives blood as it circulates back from the rest of the body. Insufficient supply of blood from the ventricles, to the organs in the body, leads to congestive heart failure. Of the four different classes of congestive heart failure, in class I and II, the individuals do not experience any major symptoms, and the problem of congestive heart failure can be controlled by making lifestyle changes, meditation and exercise. However, in the class III and IV stages, the patient’s condition is severe and the problem can only be controlled through proper treatment. There are many symptoms of congestive heart failure including irregular heartbeat, fatigue, shortness of breath, edema, chest pain, wheezing, fainting and weight gain.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/congestive-heart-failure-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of congestive heart failure therapeutics include Glaxosmithkline plc, Amgen Inc., Merck Sharp & Dohme Co, Bayer Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research and Development, LLC, Scios, Inc., Quantum Genomics SA, AstraZeneca plc, Bristol-Myers Squibb etc.

Diabetic Macular Edema Therapeutics Pipeline Analysis, 2017 – Collaboration and Other Developments

As estimated worldwide in 2011, the number of peoples with diabetes were around 346 million and its number is unceasingly getting bigger. It is expected to be double in number by 2030. Diabetic retinopathy and diabetic macular edema is occurring, which leads to the vision loss. These adverse conditions mostly occur in patient having high blood sugar level and high blood pressure. Therefore, the consequential increase in growth of diabetic macular edema therapeutics pipeline is observed.

Explore Report at: https://www.psmarketresearch.com/market-analysis/diabetic-macular-edema-therapeutics-pipeline-analysis

Diabetic macular edema became the foremost cause of vision loss in diabetic patients and working-aged adults. Diabetic macular edema is generally a building up of fluid in macula region in retina, which is present at the back of the eye and responsible for making sharp and straight-headed vision with macula. Swelling and thickening of macula majorly affecting vision by distorting it. The accumulation of fluid causes the leakage which can damage the blood vessels present near retina. The foremost cause of diabetic macular edema is diabetic retinopathy, but in some cases, it can subsequently occur after an eye surgery. It is also found that inflammation in eye can cause diabetic macular edema. Theprimary symptoms of diabetic macular edema is the wavy or blurred vision, in which colour may be faded. If it occurs to only one eye, the blurry vision will not be noticed until the condition become severe.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/diabetic-macular-edema-therapeutics-pipeline-analysis/toc-sample

In March 2016, F Hoffmann-La Roche AG, Inc. started a Phase II clinical study on drug RO6867461, in participants with center-involving Diabetic macular edema. In November 2016, Regeneron Pharmaceuticals, Inc. started a Phase IIIb of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with Diabetic Macular Edema.

Some of the companies having a pipeline of diabetic macular edema therapeutics include Regeneron Pharmaceuticals, Inc., Bayer AG, Allergan, Clearside Biomedical, Inc., Novartis AG, Chengdu Kanghong Biotech Co., Ltd., ThromboGenics NV, F Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Valeant Pharmaceuticals International, Inc.

Bronchitis Therapeutics Pipeline Analysis 2017 – Clinical Trials & Results, Collaboration and Other Developments

Bronchitis therapeutic pipeline is likely to experience a positive trend in future due to decreasing quality of the air and increasing smoking. Prevalence of bronchitis is increasing due to environmental factors, genetic factors, infections, industrial pollution, less physical activity and smoking. Some of the main factors driving the pipeline analysis for bronchitis include increasing treatment cost, increasing high rate of hospitalizations due to chronic bronchitis, increasing alpha-1-antitrypsin (AAt) deficiency, low market penetration of effective drugs and increasing health awareness. According to Centers for Disease Control and Prevention, around 9.3 million people were diagnosed with chronic bronchitis in U.S in 2015. Chronic bronchitis is the third leading cause of deaths in the U.S. According to the data by American Lung Association (ALA) the risk of chronic bronchitis increases with age. Among people over 65 years old, the rate is 64.2 per 1,000 persons. For the people aged between 18 to 44year, the rate was 28.6 per 1,000 persons. The rate at which the disease affects the females is almost double, as compared to males.

Explore Report at: https://www.psmarketresearch.com/market-analysis/bronchitis-therapeutics-pipeline-analysis

Bronchitis is a condition which involves inflammation of bronchial tubes due to infection. This results in much more mucus with cough. There are two types of bronchitis, acute bronchitis and chronic bronchitis. Acute bronchitis is usually more common form of bronchitis which does not cause much problems. It includes common cold or flu which lasts for few days or weeks. Chronic bronchitis can also result in chronic obstructive pulmonary disease (COPD). Bronchitis is caused by either viruses, bacteria, or other irritant particles such as dust, fumes, air pollution and others, same as in the case of cold or flu. The production of more mucus results in problem in breathing with smaller opening for air to flow. The symptoms of bronchitis include fever, chest congestion, breath shortening, body aches, wheezing sound while breathing, headaches, cough with mucus and runny nose. Bronchitis is diagnosed by lung function test, chest X-ray, blood test, mucus testing and measuring oxygen levels in blood. The disease can be treated by using inhalers, bronchodilators, oxygen therapy, anti-inflammatory medicines, glucocorticoid steroids, antibiotics and over-the-counter pain relievers. Some of the home remedies can also be used to treat bronchitis like steam and drinking more water.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/bronchitis-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of bronchitis therapeutics include EmeraMed Ltd., Vertex Pharmaceuticals Incorporated, SolAeroMed Inc., Novartis AG, AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Dompé Farmaceutici S.p.A, Invion Limited, Mucosis B.V.

Nasopharyngeal Cancer Therapeutics Pipeline Analysis 2017 – Clinical Trials & Results and Other Developments

Nasopharyngeal cancer therapeutic pipeline analysis is likely to grow mainly due to the rising prevalence of nasopharyngeal cancer, globally. Some of the main factors driving the pipeline analysis for nasopharyngeal cancer includes increasing geriatric population, rising tobacco and alcohol consumption and increasing prevalence of nasopharyngeal cancer, untapped market as being a rare form of head and neck cancer and increasing health awareness. According to American Cancer Society, the nasopharyngeal cancer is more common in some parts of North Africa and Asia, particularly in Southern China. It is also more common in countries such as Canada and Alaska and among some immigrant groups in the U.S., such as recent Chinese immigrants. Nasopharyngeal cancer is found to be more prevalent in males as compared to females.

Explore Report at: https://www.psmarketresearch.com/market-analysis/nasopharyngeal-cancer-therapeutics-pipeline-analysis

Nasopharyngeal cancer is the rarest form of head and neck cancer. Nasopharyngeal cancer is the tumor that occurs in nasopharynx which is the upper part of the throat behind the nose and near the base of skull. Two different types of tumors that can develop in nasopharynx include benign tumors and malignant tumors. Some of the risks factors for nasopharyngeal cancer include salt-cured fish and meat rich diet, epstein-barr viral infection and increasing tobacco and alcohol consumption. The disease occurs usually more in people who are under 55years of age and have a family history of nasopharyngeal cancer or have the chances to develop Epstein-barr viral infection. The symptoms of nasopharyngeal cancer include blurred vision, ear infection, headache, nose bleeding, lump in neck and numbness. Nasopharyngeal cancer is diagnosed by consulting an otolaryngologist for the physical examination. Further, chest X-ray, CT scan, MRI, ultrasound, blood tests, Epstein-barr viral infection testing and biopsy are done for the confirmation of the disease. The treatment for nasopharyngeal cancer includes, chemotherapy, radiation therapy, surgery and biological drug treatment.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/nasopharyngeal-cancer-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of nasopharyngeal cancer therapeutics include Atara Biotherapeutics, Inc., AVEO Pharmaceuticals, Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, arGEN-X BVBA, Merck & Co., Inc., Tessa Therapeutics Pte Ltd.

Juvenile idiopathic arthritis Therapeutics Pipeline Analysis 2017 – Designation, Collaboration, and Other Developments

The expanding pipeline for juvenile idiopathic arthritis can be attributed to the increase in its prevalence. One of the major factor that stimulate the growth of pipeline and research is that the cause of juvenile idiopathic arthritis is not known. The juvenile idiopathic arthritis occurs mostly in children before 16 years of age. Since the disease occurs only in children, so the safety and efficacy concerns of the drugs is given preference so that it can be treated without any side effects. Some of the other factors driving the pipeline growth include, raising awareness of health issues among children and less number of drugs available for therapy against juvenile idiopathic arthritis. Currently, one in 1,000 child in the U.S. suffers with juvenile idiopathic arthritis. Females are more susceptible to juvenile idiopathic arthritis than males.

Explore Report at: https://www.psmarketresearch.com/market-analysis/juvenile-idiopathic-arthritis-therapeutics-pipeline-analysis

Juvenile idiopathic arthritis can be symptomatized as swelling, joint pain, tenderness, stiffness and fever that last for approximately more than 6 weeks. Juvenile idiopathic arthritis, mostly occurs when body’s immune system erroneously attacks its own healthy tissues and cells, which result in inflammation, pain, heat, redness and swelling. Researchers have studied that, either environmental factors or genetic tendency of child act as triggers for the occurrence of the disease. Juvenile idiopathic arthritis affects mostly joints in knees, hand and feet. Sometimes, severe complication can occur in children with juvenile idiopathic arthritis such as eye inflammation. Currently, no medical test is approved for diagnosis of juvenile idiopathic arthritis. Physicians diagnose juvenile idiopathic arthritis by examining the medical history of the patient and the result of other tests that help in ruling out other morbidities.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/juvenile-idiopathic-arthritis-therapeutics-pipeline-analysis/toc-sample

In 2011, Momenta Pharmaceuticals, Inc. collaborated with Shire Plc for the development and commercialization of M923, which is a proposed biosimilar of Humira (adalimumab) but the collaboration was later terminated. In June 2010, F Hoffman-la-Roche announced that RoACTEMRA (known as ACTEMRA outside Europe) is highly effective in improving the signs and symptoms of systemic juvenile idiopathic arthritis, which currently has no licensed treatments. RoACTEMRA is also well tolerated in children with systemic juvenile idiopathic arthritis and has a safety profile similar to adults with rheumatoid arthritis.

Some of the companies having a pipeline of juvenile idiopathic arthritis therapeutics include, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Pfizer, Inc., Novartis AG.